Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP

Pharmacogenomics Journal

Volumn 20, Issue 2, 2020, Pages 329-341

  Wigmore, Eleanor M ^a   Hafferty, Jonathan D ^a   Hall, Lynsey S ^a   Howard, David M ^a   Clarke, Toni Kim ^a   Fabbri, Chiara ^b,c   Lewis, Cathryn M ^b   Uher, Rudolf ^b,d   Navrady, Lauren B ^a   Adams, Mark J ^a   Zeng, Yanni ^a   Campbell, Archie ^a   Gibson, Jude ^a   Thomson, Pippa A ^a   Hayward, Caroline ^e   Smith, Blair H ^f   Hocking, Lynne J ^g   Padmanabhan, Sandosh ^h   Deary, Ian J ^a   Porteous, David J ^a   Mors, Ole ^i,j   Mattheisen, Manuel ^j,k,l,m   Nicodemus, Kristin K ^a   McIntosh, Andrew M ^a   more..

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g UNIVERSITY OF ABERDEEN   (United Kingdom)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j Aarhus   (Denmark)

^k AARHUS UNIVERSITY   (Denmark)

^l KAROLINSKA INSTITUTE   (Sweden)

^m STOCKHOLM COUNTY COUNCIL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; NORTRIPTYLINE;

ARTICLE; DEPRESSION; DISTRESS SYNDROME; DRUG RESPONSE; DRUG USE; FAMILY; GENETIC CORRELATION; GENETIC RISK SCORE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HERITABILITY; HUMAN; MOOD DISORDER; NEUROSIS; PEDIGREE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY RESISTANCE; ADULT; COHORT ANALYSIS; DATA ANALYSIS; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEALTH SERVICE; HEALTH SURVEY; MALE; META ANALYSIS; MIDDLE AGED; PROCEDURES; SCOTLAND; TREATMENT RESISTANT DEPRESSION;

ADULT; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DATA ANALYSIS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG PRESCRIPTIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; SCOTLAND;

EID: 85060909626     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/s41397-019-0067-3     Document Type: Article

References (69)

1. Ustün T, Ayuso-Mateos J, Chatterji S, Mathers C, Murray C. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–92.
2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800.
3. Rush A, Trivedi M, Wisniewski S, Nierenberg A, Stewart J, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.
4. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167:555–64.
5. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66:966–75.
6. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67:133–8.
7. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med. 2012;9:e1001326.
8. Myung W, Kim J, Lim SW, Shim S, Won HH, Kim S, et al. A genome-wide association study of antidepressant response in Koreans. Transl Psychiatry. 2015;5:e672.
9. Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry. 2015;5:e553.
10. Cocchi E, Fabbri C, Han C, Lee SJ, Patkar AA, Masand PS, et al. Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry. 2016;16:106.
11. Investigators G, Investigators M. Investigators SD. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170:207–17.
12. Li QS, Tian C, Seabrook GR, Drevets WC, Narayan VA. Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response. Transl Psychiatry. 2016;6:e889.
13. Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry. 2014;59:62–75.
14. García-González J, Tansey KE, Hauser J, Henigsberg N, Maier W, Mors O, et al. Pharmacogenetics of antidepressant response: A polygenic approach. Prog Neuropsychopharmacol Biol Psychiatry. 2017;75:128–34.
15. De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. Psychiatry Res. 2016;240:421–30.
16. Amital D, Fostick L, Silberman A, Beckman M, Spivak B. Serious life events among resistant and non-resistant MDD patients. J Affect Disord. 2008;110:260–4.
17. Takahashi M, Shirayama Y, Muneoka K, Suzuki M, Sato K, Hashimoto K. Low openness on the revised NEO personality inventory as a risk factor for treatment-resistant depression. PLoS ONE. 2013;8:e71964.
18. McGirr A, Van den Eynde F, Chachamovich E, Fleck MP, Berlim MT. Personality dimensions and deep repetitive transcranial magnetic stimulation (DTMS) for treatment-resistant depression: a pilot trial on five-factor prediction of antidepressant response. Neurosci Lett. 2014;563:144–8.
19. Bacanu SA, Whittaker JC, Nelson MR. How informative is a negative finding in a small pharmacogenetic study? Pharm J. 2012;12:93–95.
20. Bergen SE, Petryshen TL. Genome-wide association studies of schizophrenia: does bigger lead to better results? Curr Opin Psychiatry. 2012;25:76–82.
21. Baker LA. Do our “big data” in genetic analysis need to get bigger? Psychophysiology. 2014;51:1321–2.
22. Wimberley T, Støvring H, Sørensen HJ, Horsdal HT, MacCabe JH, Gasse C. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016;3:358–66.
23. O’Dushlaine C, Ripke S, Ruderfer DM, Hamilton SP, Fava M, Iosifescu DV, et al. Rare copy number variation in treatment-resistant major depressive disorder. Biol Psychiatry. 2014;76:536–41.
24. Ruderfer DM, Charney AW, Readhead B, Kidd BA, Kähler AK, Kenny PJ, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry. 2016;3:350–7.
25. Smith B, Campbell H, Blackwood D, Connell J, Connor M, Deary I, et al. Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability. BMC Med Genet. 2006;7:74.
26. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, et al. Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. Int J Epidemiol. 2013;42:689–700.
27. Joint Formulary Committee. British national formulary. 73 edn. London: BMJ Group and Pharmaceutical Press; 2017.
28. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83–91.
29. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649–59.
30. Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry. 2017;74:9–10.
31. Ruhé HG, van Rooijen G, Spijker J, Peeters FP, Schene AH. Staging methods for treatment resistant depression. A systematic review. J Affect Disord. 2012;137:35–45.
32. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
33. Iniesta R, Malki K, Maier W, Rietschel M, Mors O, Hauser J, et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res. 2016;78:94–102.
34. Kerr S, Campbell A, Murphy L, Hayward C, Jackson C, Wain L, et al. Pedigree and genotyping quality analyses of over 10,000 DNA samples from the Generation Scotland: Scottish Family Health Study. BMC Med Genet. 2013;14:38.
35. Nagy R, Boutin TS, Marten J, Huffman JE, Kerr SM, Campbell A, et al. Exploration of haplotype research consortium imputation for genome-wide association studies in 20,032 Generation Scotland participants. Genome Med. 2017;9:23.
36. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48:1279–83.
37. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010;34:816–34.
38. Yang J, Lee S, Goddard M, Visscher P. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011;88:76–82.
39. Zaitlen N, Kraft P, Patterson N, Pasaniuc B, Bhatia G, Pollack S, et al. Using extended genealogy to estimate components of heritability for 23 quantitative and dichotomous traits. PLoS Genet. 2013;9:e1003520.
40. Yang J, Zaitlen NA, Goddard ME, Visscher PM, Price AL. Advantages and pitfalls in the application of mixed-model association methods. Nat Genet. 2014;46:100–6.
41. Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45:730–8.
42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.
43. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190–1.
44. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.
45. Hadfield J. MCMC methods for multi-response generalized linear mixed models: The MCMCglmm R package. J Stat Softw. 2010;33:1–22.
46. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52.
47. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
48. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet. 2011;43:977–83.
49. Palla L, Dudbridge F. A fast method that uses polygenic scores to estimate the variance explained by genome-wide marker panels and the proportion of variants affecting a trait. Am J Hum Genet. 2015;97:250–9.
50. Zeng Y, Navarro P, Xia C, Amador C, Fernandez-Pujals AM, Thomson PA et al. Shared Genetics and Couple-Associated Environment Are Major Contributors to the Risk of Both Clinical and Self-Declared Depression. EBioMedicine 2016;14:161–167.
51. Rozen R, Vockley J, Zhou L, Milos R, Willard J, Fu K, et al. Isolation and expression of a cDNA encoding the precursor for a novel member (ACADSB) of the acyl-CoA dehydrogenase gene family. Genomics. 1994;24:280–7.
52. Villaseñor A, Ramamoorthy A, Silva dos Santos M, Lorenzo MP, Laje G, Zarate C, et al. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br J Pharmacol. 2014;171:2230–42.
53. Wang W, Grimmer JF, Van De Water TR, Lufkin T. Hmx2 and Hmx3 homeobox genes direct development of the murine inner ear and hypothalamus and can be functionally replaced by Drosophila Hmx. Dev Cell. 2004;7:439–53.
54. Papiol S, Arias B, Gastó C, Gutiérrez B, Catalán R, Fañanás L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104:83–90.
55. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31:464–8.
56. Ling J, Wu X, Fu Z, Tan J, Xu Q. Systematic analysis of gene expression pattern in has-miR-197 over-expressed human uterine leiomyoma cells. Biomed Pharmacother. 2015;75:226–33.
57. Cohen J. A power primer. Psychol Bull. 1992;112:155–9.
58. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2016;102:37–44.
59. Peters EJ, Reus V, Hamilton SP. The ABCB1 transporter gene and antidepressant response. F1000 Biol Rep. 2009;1:23.
60. Hodgson K, Tansey K, Dernovsek MZ, Hauser J, Henigsberg N, Maier W, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol. 2014;28:133–41.
61. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther. 1996;60:522–34.
62. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry. 2010;71:1482–7.
63. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009;29:39–43.
64. Kivimäki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care. 2010;33:2611–6.
65. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(Suppl 13):23–29.
66. Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70:177–84.
67. Berlim M, Turecki G. Definition, assessment, and staging of treatment—resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007;52:46–54.
68. Menke A, Binder EB. Epigenetic alterations in depression and antidepressant treatment. Dialog Clin Neurosci. 2014;16:395–404.
69. Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13:395–405.